Citation

Shakya S, Harris SJ. Drug Alcohol Depend. Rep. 2022; 3: e100042.

Copyright

(Copyright © 2022, Elsevier Publishing)

DOI

10.1016/j.dadr.2022.100042

PMID

unavailable

Abstract

BACKGROUND: The opioid overdose crisis remains of critical concern after historic increases in overdose mortality in the United States between 2020 and 2021. Improving access to buprenorphine --a partial opioid agonist and one of three FDA-approved medications for opioid use disorder (OUD) treatment-- and reducing inappropriate opioid prescriptions may help curb mortality. Here, we examined the impact of Medicaid expansion and pain management clinic laws on opioid prescription rates and buprenorphine availability.

METHODS: We examined both retail opioid prescriptions per 100 persons in the state population using data from the Centers for Disease Control and Prevention and data on buprenorphine distributions in kilograms per 100,000 persons in the state population from the Automated Reports and Consolidated Ordering System database. We employed difference-in-difference frameworks to estimate the impact of Medicaid expansion on buprenorphine access and retail opioid prescription rates. Models considered three separate treatment variables: Medicaid expansion, pain management clinic ("pill mill") laws, and the interaction of Medicaid expansion and pain management clinic laws.

RESULTS: Findings showed that Medicaid expansion was associated with increased access to buprenorphine in expansion states that also employed more stringent supply-side policies, including pain management clinic laws, relative to states that did not implement policies targeting the over-supply of prescription opioids over the same time period.

CONCLUSIONS. Together, Medicaid expansion and policies limiting inappropriate opioid prescriptions show promise for improving the accessibility of buprenorphine treatment for OUD.

Language: en

Keywords

Buprenorphine; Medicaid; Opioid use disorder; Pain management clinic